Knockout animals
US6576813B2 · kind B2 · utility
1Cited by
1References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 18, 1999 |
| Grant date | Jun 10, 2003 |
| Priority date | — |
| Expiry date | Nov 18, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/03
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Transgenic mice are constructed by binding the “hHB-EGF/DTR” gene to the downstream of an albumin enhancer/promoter that is expressed specifically in hepatic parenchymal cells and introducing this unit into mice. After the “hHB-EGF/DTR” gene has been confirmed to be expressed specifically in hapatic cells, diphtehria toxin is administered to the transgenic mice to examine whether the hepatic parenchymal cells are disrupted. The hepatic cells of the transgenic mice can be selectively dirupted depending on the administration period of the diphtheria toxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.